This company listing is no longer active
CStone Pharmaceuticals Future Growth
Future criteria checks 2/6
CStone Pharmaceuticals is forecast to grow earnings and revenue by 34.1% and 29.9% per annum respectively while EPS is expected to grow by 32.7% per annum.
Key information
34.1%
Earnings growth rate
32.7%
EPS growth rate
| Biotechs earnings growth | 41.1% |
| Revenue growth rate | 29.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 28 Feb 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 1,014 | -268 | N/A | N/A | 1 |
| 12/31/2024 | 903 | -479 | N/A | N/A | 2 |
| 12/31/2023 | 637 | -591 | N/A | N/A | 2 |
| 6/30/2023 | 481 | -750 | -539 | -510 | N/A |
| 3/31/2023 | 481 | -827 | -626 | -561 | N/A |
| 12/31/2022 | 481 | -903 | -714 | -612 | N/A |
| 9/30/2022 | 454 | -1,205 | -966 | -842 | N/A |
| 6/30/2022 | 426 | -1,508 | -1,219 | -1,072 | N/A |
| 3/31/2022 | 335 | -1,714 | -1,426 | -1,278 | N/A |
| 12/31/2021 | 244 | -1,920 | -1,633 | -1,484 | N/A |
| 9/30/2021 | 681 | -1,622 | -1,241 | -1,103 | N/A |
| 6/30/2021 | 1,118 | -1,324 | -848 | -722 | N/A |
| 3/31/2021 | 1,079 | -1,272 | -714 | -615 | N/A |
| 12/31/2020 | 1,039 | -1,221 | -580 | -508 | N/A |
| 9/30/2020 | 519 | -1,482 | -971 | -920 | N/A |
| 6/30/2020 | -2 | -1,744 | -1,362 | -1,333 | N/A |
| 3/31/2020 | -1 | -1,906 | -1,227 | -1,207 | N/A |
| 12/31/2019 | N/A | -2,069 | -1,091 | -1,081 | N/A |
| 9/30/2019 | 11 | -1,688 | -907 | -898 | N/A |
| 6/30/2019 | 12 | -1,246 | -706 | -699 | N/A |
| 3/31/2019 | 12 | -858 | -752 | -745 | N/A |
| 12/31/2018 | 13 | -470 | -799 | -791 | N/A |
| 9/30/2018 | 13 | -336 | -693 | -679 | N/A |
| 12/31/2017 | 10 | -107 | -253 | -240 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2616 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2616 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2616 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2616's revenue (29.9% per year) is forecast to grow faster than the Hong Kong market (8.1% per year).
High Growth Revenue: 2616's revenue (29.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2616's Return on Equity is forecast to be high in 3 years time